The first generation of RNA therapeutics proved it could make a protein. The next one is being built to last longer and go further. Orna Therapeutics, a Cambridge biotech spun out of MIT in 2019, is betting its engineered circular RNA, or oRNA, can do both. By closing the loop on the molecule, the company aims to create drugs that are more stable and express therapeutic proteins for days, not hours. Its bigger ambition is to use this durable payload, delivered via lipid nanoparticles (LNPs), to reach tissues beyond the liver and tackle diseases like cancer with in vivo cell therapies [Orna Therapeutics, retrieved 2024].
The Circular RNA Wedge
Orna's core technical bet is a structural one. Linear messenger RNA, the workhorse behind COVID-19 vaccines, is inherently fragile. Cellular enzymes quickly degrade its exposed ends, limiting how long it can produce a protein. Orna's oRNA technology eliminates those ends by joining the RNA molecule into a continuous circle. The company claims this circular architecture confers "improved stability and prolonged protein expression" compared to linear RNA, a fundamental advantage for therapies that need sustained action [Orna Therapeutics, retrieved 2024].
The delivery challenge is equally critical. First-wave mRNA drugs largely target the liver because standard LNPs naturally accumulate there. Orna asserts its proprietary LNP formulations can deliver oRNA to other sites, "unlocking the treatment of a far greater span of diseases" [Orna Therapeutics, retrieved 2024].
A Pipeline Built for In Vivo Engineering
Orna's most advanced and conceptually bold program is an in vivo CAR T-cell therapy. Today's CAR-T treatments are complex and expensive: a patient's T cells are extracted, genetically reprogrammed in a lab to attack cancer, and then reinfused. Orna's approach is to skip the lab entirely. The plan is to inject an LNP carrying oRNA that encodes the CAR directly into the patient, programming their T cells inside the body. The company anticipates filing a Clinical Trial Application for this program by the end of 2025, with a first-in-human study expected in early 2026 [Orna Therapeutics, retrieved 2026].
The Merck Validation and Funding Firepower
In biotech, platform potential is often measured by the caliber of partners willing to pay for it. In August 2022, Orna secured a landmark deal with pharmaceutical giant Merck & Co. The agreement included a $150 million upfront payment, with $100 million of that as an equity investment in Orna [Merck, August 2022]. More importantly, it outlined up to $3.5 billion in potential development, regulatory, and sales milestones, plus royalties on future sales [Merck, August 2022].
That confidence is reflected in Orna's balance sheet. The company has raised a total of $321 million in venture equity, anchored by a $221 million Series B in mid-2022 led by MPM Capital [BioPharma Dive, August 2022].
| Metric | Value |
|---|---|
| Seed (2019) | Undisclosed |
| Series A (2021) | 80 $M |
| Series B (2022) | 221 $M |
| Merck Upfront (2022) | 150 $M |
The Team Behind the Loop
Orna's founding story is deeply academic, with roots in one of the world's leading bioengineering labs. The company was founded based on the work of three MIT professors: Daniel G. Anderson, Robert S. Langer, and Giovanni Traverso [MIT News, 2022].
To translate this science into a company, Orna brought in seasoned operators. Tom McCauley, Ph.D., served as CEO. The R&D engine is led by Joseph Bolen, Ph.D., who was appointed Chief Executive Officer in March 2025 [PRNewswire, March 2025]. Bolen was previously the Chief Scientific Officer and President of R&D at Moderna [Orna Therapeutics, retrieved 2024].
Technical Breakdown and Scale Risks
The promise of circular RNA is clear, but the path to a commercial drug is paved with technical hurdles. The central tradeoff Orna is making involves immunogenicity. While the circular structure may avoid certain immune sensors that recognize linear RNA ends, the molecule itself is still foreign. Manufacturing presents another layer of complexity. Producing large quantities of pure, circular RNA is a different and potentially more challenging process than manufacturing linear mRNA.
Finally, the competitive landscape is moving fast. Orna is not alone in pursuing next-generation RNA formats. Competitors like ReNAgade Therapeutics (which Orna acquired in 2024), Replicate Bioscience, and others are exploring similar frontiers in stability and delivery [Perplexity Sonar Pro Brief].
The Next Twelve Months
All strategic roads for Orna now lead to the clinic. The filing of its Clinical Trial Application for the in vivo CAR-T program by year-end 2025 is the critical near-term milestone. Initiating the first-in-human study in early 2026 will provide the first real-world data on oRNA's safety, tolerability, and biological activity in patients.
Sources
- [Orna Therapeutics, retrieved 2024] Company Website | https://www.ornatx.com
- [Merck, August 2022] Merck and Orna Therapeutics Announce Strategic Collaboration and License Agreement | https://www.merck.com/news/merck-and-orna-therapeutics-announce-strategic-collaboration-and-license-agreement-to-develop-innovative-ornatm-rna-based-vaccines-and-therapeutics/
- [BioPharma Dive, August 2022] Next-generation RNA technologies: making longer-lasting drugs with a broader reach | https://www.biopharmadive.com/news/rna-next-gen-drugs-technology-biotech-startups/630203/
- [MIT News, 2022] Orna Therapeutics | https://news.mit.edu/2022/orna-therapeutics-0021
- [Orna Therapeutics, retrieved 2026] Pipeline Update | https://www.ornatx.com
- [PRNewswire, March 2025] Joseph Bolen Appointed CEO of Orna Therapeutics | https://www.prnewswire.com
- [Perplexity Sonar Pro Brief] Competitive Landscape Analysis
- [Orna Therapeutics, retrieved 2024] Leadership Team | https://www.ornatx.com/about